France Reaches Agreement With Gilead To Drop Prices Of Hepatitis C Treatment 31/03/2017 by Intellectual Property Watch 2 Comments Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)The French Ministry of Social Affairs and Health announced today that the ministry has negotiated with pharmaceutical company Gilead to bring down the prices of hepatitis C medicines. According to the ministry’s press release (in French), the price decrease for the drugs Harvoni and Sovaldi is described as “very substantial.” New prices are expected to come into effect on 1 April. For Sovaldi, it will drop from €41,000 euros to less than €28,700 euros for the treatment of hepatitis C, it said. The new prices will allow continued universal access to hepatitis C for patients in France, the release said. Hepatitis C treatments are integrally supported by the French social security system, which will benefit from those new prices, it added. Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window) Related "France Reaches Agreement With Gilead To Drop Prices Of Hepatitis C Treatment" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
[…] negotiated with pharmaceutical company Gilead to bring down the prices of hepatitis C medicines. Fonte:https://www.ip-watch.org/2017/03/31/france-reaches-agreement-gilead-drop-prices-hepatitis-c-tr… Author: Catherine […] Reply